Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report Download FREE Resources

Published: June 25, 2025 Report Code: GDHC319PIDR-7M-ST

Select Item

This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034.

GlobalData estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%.
The major drivers of growth in the PD market will be the launch of new disease modifying therapies (DMTs) with new mechanisms of action (MOAs) across the 7MM that target MS disease progression which will also increase treatment rates during the forecast period, and a trend towards the use of high-efficacy treatments such as anti-CD20 monoclonal antibodies (mAbs), which have high annual costs of therapy and high patient compliance rates.
Brand erosion due to the emergence of biosimilars and generic small molecules will hamper the future growth of the global MS market.

Scope

Overview of Multiple Sclerosis, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Multiple Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Multiple Sclerosis therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Multiple Sclerosis treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global Multiple Sclerosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

  • Report deliverables include a Word report and an Excel-based forecast model

  • Forecast includes the 7 major markets (7MM)

  • Forecast covers the period 2020-2030

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM Multiple Sclerosis therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Multiple Sclerosis therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

List of Contents

List of Tables

List of Figures

About GlobalData

1 Multiple Sclerosis: Executive Summary

1.1 The MS market will grow to $25.9 billion

1.2 Current players are to remain leaders in the MS market in 2034

1.3 Opportunities remain to fulfill key unmet needs

1.4 Novel late-stage pipeline drugs will be a key driver of growth

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

3.2.1 Radiologically isolated syndrome and clinically isolated syndrome

3.2.2 Relapsing-remitting MS

3.2.3 Secondary progressive MS

3.2.4 Primary progressive MS

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of MS

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of MS by type

4.5 Epidemiological forecast for MS (2024–34)

4.5.1 Diagnosed prevalent cases of MS

4.5.2 Age-specific diagnosed prevalent cases of MS

4.5.3 Sex-specific diagnosed prevalent cases of MS

4.5.4 Diagnosed prevalent cases of MS by type

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis overview

5.2 Treatment overview

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 A curative therapy

7.3 Preventing disease progression and addressing progressive forms of MS

7.4 Safety and tolerability of DMTs

7.5 Biomarkers for MS progression and treatment response

8 R&D Strategies

8.1 Overview

8.1.1 Reformulations and optimizing delivery systems

8.1.2 Bruton’s tyrosine kinase inhibitors

8.1.3 Cell and gene therapies in MS

8.2 Clinical trials design

8.2.1 Primary endpoints

8.2.2 Active comparator versus placebo

8.2.3 Inclusion criteria – age

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

13.7 Contact Us

Table

Table 1: MS: Key Metrics in the 7MM

Table 2: Risk factors and comorbid conditions associated with MS

Table 3: Revised 2017 McDonald criteria for the diagnosis of MS

Table 4: Treatment guidelines for MS

Table 5: Top three disease-modifying therapies prescribed for MS, by market, 2018

Table 6: Leading disease-modifying drugs for the treatment of MS, 2023

Table 7: MS market – global drivers and barriers, 2020-30

Table 8: Key events impacting sales for MS in the US, 2020-30

Table 9: MS market – drivers and barriers in the US, 2020-30

Table 10: Key events impacting sales for MS in the 5EU, 2020-30

Table 11: MS market – drivers and barriers in the 5EU, 2020-30

Table 12: Key events impacting sales for MS in Japan, 2020-30

Table 13: MS market – drivers and barriers in Japan, 2020-30

Table 14: High-prescribing physicians (non-KOLs) surveyed, By country

Figures

Figure 1: Global sales forecast by country for MS in 2020 and 2030

Figure 2: Analysis of the company portfolio gap in multiple sclerosis during the forecast period

Figure 3: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of MS during the forecast period

Figure 4: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of MS during the forecast period

Figure 5: Accrual of disability in the three subtypes of MS

Figure 6: 7MM, diagnosed incidence of MS (cases per 100,000 population), men and women, all ages, 2020

Figure 7: 7MM, diagnosed prevalence of MS (%), men and women, all ages, 2020

Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of MS

Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS

Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of MS by type

Figure 11: 7MM, diagnosed incident cases of MS, N, both sexes, all ages, 2020

Figure 12: 7MM, age-specific diagnosed incident cases of MS, N, both sexes, all ages, 2020

Figure 13: 7MM, sex-specific diagnosed incident cases of MS, N, all ages, 2020

Figure 14: 7MM, diagnosed prevalent cases of MS, N, both sexes, all ages, 2020

Figure 15: 7MM, age-specific diagnosed prevalent cases of MS, N, both sexes, all ages, 2020

Figure 16: 7MM, sex-specific diagnosed prevalent cases of MS, N, all ages, 2020

Figure 17: 7MM, diagnosed prevalent cases of MS by type, N, both sexes, all ages, 2020

Figure 18: Expanded Disability Status Scale (EDSS)

Figure 19: Algorithm for the treatment of MS with disease-modifying therapy (DMT)

Figure 20: Unmet needs and opportunities in MS

Figure 21: Overview of the development pipeline in MS

Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for MS treatment in the 7MM during the forecast period

Figure 23: Competitive assessment of the injectable pipeline drugs benchmarked against the SOC Ocrevus

Figure 24: Competitive assessment of the oral pipeline drugs benchmarked against the SOC Tecfidera

Figure 25: Analysis of the company portfolio gap in MS during the forecast period

Figure 26: Global (7MM) sales forecast by country for multiple sclerosis in 2020 and 2030

Figure 27: Global (7MM) sales forecast by therapy class for multiple sclerosis in 2020 and 2030

Figure 28: Sales forecast by class for MS in the US in 2020 and 2030

Figure 29: Sales forecast by class for MS in the 5EU in 2020 and 2030

Figure 30: Sales forecast by class for MS in Japan in 2020 and 2030

Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Multiple Sclerosis reports
Pharmaceuticals
New
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
$3,450 | May 2026
Pharmaceuticals
New
Q1 2026 CRO Activity and Intel Report
$1,870 | May 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, April 2026
$2,950 | May 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

  • Access a live Multiple Sclerosis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more